| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1047065327 |
| P356 | DOI | 10.2165/0002512-200825110-00002 |
| P698 | PubMed publication ID | 18947259 |
| P50 | author | Stefania Maggi | Q114171748 |
| Angela M Abbatecola | Q114434696 | ||
| Giuseppe Paolisso | Q37634089 | ||
| P2860 | cites work | The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion | Q27863756 |
| Glucagon-like peptide-1 receptor is involved in learning and neuroprotection | Q28202403 | ||
| Frailty in older adults: evidence for a phenotype | Q28205094 | ||
| Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study | Q28213764 | ||
| Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes | Q28262769 | ||
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial | Q28277510 | ||
| Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors | Q30320205 | ||
| Diabetes in elderly adults | Q31978719 | ||
| Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of the Epidemiology of Vascular Aging Study. | Q32050146 | ||
| Management of type 2 diabetes mellitus in the elderly: special considerations | Q32090951 | ||
| Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes | Q33209301 | ||
| Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release | Q33423614 | ||
| Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable | Q34061916 | ||
| Conceptualisation and measurement of frailty in elderly people | Q34087251 | ||
| Prevalence, expenditures, and complications of multiple chronic conditions in the elderly | Q34157941 | ||
| Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. | Q34466568 | ||
| Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). | Q34618193 | ||
| Ageing and diabetes: implications for brain function | Q34635793 | ||
| Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy | Q34689865 | ||
| Prevalence and risk factors for urinary incontinence in women with type 2 diabetes and impaired fasting glucose: findings from the National Health and Nutrition Examination Survey (NHANES) 2001-2002. | Q35011778 | ||
| Microalbuminuria as predictor of increased mortality in elderly people | Q35167321 | ||
| Frailty in the elderly: contributions of sarcopenia and visceral protein depletion | Q35567410 | ||
| Minireview: Glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system | Q35714885 | ||
| Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells | Q35772023 | ||
| Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus | Q36327020 | ||
| The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers | Q36535937 | ||
| Risk factors for falls in older disabled women with diabetes: the women's health and aging study | Q36628744 | ||
| A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. | Q51483637 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. | Q51483804 | ||
| Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. | Q51483830 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. | Q51484788 | ||
| Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. | Q51484798 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. | Q51489068 | ||
| Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects | Q51606971 | ||
| Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. | Q51977974 | ||
| A community survey of diabetes in the elderly | Q52040749 | ||
| Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. | Q53886146 | ||
| Sarcopenic Obesity Predicts Instrumental Activities of Daily Living Disability in the Elderly | Q57760933 | ||
| Diabetes and Incidence of Functional Disability in Older Women | Q58217177 | ||
| Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose) | Q58449094 | ||
| Cardiovascular risk factors and cognitive decline in middle-aged adults | Q60692491 | ||
| Diabetes and physical disability among older U.S. adults | Q64130351 | ||
| Patterns of disability related to diabetes mellitus in older women | Q76402524 | ||
| Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines | Q80542636 | ||
| Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus | Q36715772 | ||
| Sitagliptin | Q36757596 | ||
| The role of vildagliptin in the management of type 2 diabetes mellitus | Q36800624 | ||
| Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors | Q36861085 | ||
| New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond | Q37069916 | ||
| Reported and measured physical functioning in older inner-city diabetic African Americans | Q39510112 | ||
| Alpha- and beta-cell interrelationships in health and disease | Q39940637 | ||
| Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes | Q40404408 | ||
| The prevalence of diabetic retinopathy among adults in the United States | Q40517905 | ||
| Management of diabetes in the elderly: a clinical perspective | Q40745094 | ||
| The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons | Q41678964 | ||
| Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas | Q42055798 | ||
| Longitudinal prevalence of major eye diseases. | Q42608078 | ||
| Glucagon-like peptide-1 (7-37) augments insulin release in elderly patients with diabetes | Q43603840 | ||
| Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes | Q43778779 | ||
| Effect of glucagon-like peptide 1 on non-insulin-mediated glucose uptake in the elderly patient with diabetes | Q43778860 | ||
| Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes | Q43781475 | ||
| Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers | Q43913912 | ||
| Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects | Q43915939 | ||
| The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics | Q44111090 | ||
| Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes | Q44599736 | ||
| One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. | Q44865459 | ||
| Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients | Q44865611 | ||
| Economic costs of diabetes in the US in 2002. | Q44892463 | ||
| Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial | Q44909518 | ||
| The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes | Q44995597 | ||
| Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy | Q45020436 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 | ||
| A Population-based Study of the Incidence of Complications Associated with Type 2 Diabetes in the Elderly | Q45254423 | ||
| Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. | Q45257473 | ||
| Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus | Q45306841 | ||
| alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients | Q46401204 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea | Q46458866 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| Older women with diabetes have an increased risk of fracture: a prospective study | Q46556380 | ||
| Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency | Q46563222 | ||
| Insulin resistance and risk of congestive heart failure | Q46609295 | ||
| Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea | Q46745719 | ||
| Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study | Q47693449 | ||
| Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients | Q47956988 | ||
| Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. | Q48463721 | ||
| Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort | Q48769554 | ||
| Geriatric conditions and disability: the Health and Retirement Study | Q50456300 | ||
| Association of diabetes mellitus and dementia: the Rotterdam Study | Q50989914 | ||
| Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. | Q51478110 | ||
| Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. | Q51478119 | ||
| The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. | Q51480151 | ||
| P433 | issue | 11 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 913-925 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Drugs & Aging | Q5308946 |
| P1476 | title | New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies | |
| P478 | volume | 25 |
| Q34563587 | Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options |
| Q51759934 | Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes. |
| Q37688031 | Antidiabetic oral treatment in older people: does frailty matter? |
| Q37982214 | Clinical management of elderly patients with type 2 diabetes mellitus |
| Q38113093 | Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin |
| Q38541323 | Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors |
| Q37992956 | Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? |
| Q53064501 | Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. |
| Q37799813 | Drug-induced hypoglycaemia: an update |
| Q51071499 | Effect of different diabetes mellitus treatments on functional decline and death in elderly adults with diabetes mellitus |
| Q37699685 | Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population |
| Q36649815 | Glucose and low-density lipoprotein cholesterol lowering in elderly patients with type 2 diabetes: focus on combination therapy with colesevelam HCl. |
| Q37637818 | Glucose control in the older patient: from intensive, to effective and safe |
| Q37858364 | Incretin therapies in the management of elderly patients with type 2 diabetes mellitus |
| Q37468429 | Management of type 2 diabetes mellitus in older patients: current and emerging treatment options |
| Q37886705 | Management of type 2 diabetes mellitus in the elderly: role of the pharmacist in a multidisciplinary health care team |
| Q33577712 | Optimal therapy of type 2 diabetes: a controversial challenge |
| Q34144920 | Polypharmacy and Combination Therapy in the Management of Hypertension in Elderly Patients with Co-Morbid Diabetes Mellitus |
| Q37884564 | Special considerations with insulin therapy in older adults with diabetes mellitus |
| Q27666079 | Structures of human pancreatic α-amylase in complex with acarviostatins: Implications for drug design against type II diabetes |
| Q48269534 | When Metformin Is Not Enough: Pros and Cons of SGLT2 and DPP-4 Inhibitors as a Second Line Therapy |
Search more.